Amman Bradford K. reported grant involving 250,000 shares of Vivos Therapeutics, Inc. at $0.41 for $103k on Jul 31, 2026

Grant
Form 4 code A. Grant, award, or other acquisition under Rule 16b-3(d).
Principal Accounting Officer
Principal Accounting Officer
Filed Aug 26, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
$102,500Shares × reported price
Shares traded
250,000Common Stock
Price per share
$0.41Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
250,080Direct
Trade date
Jul 31, 2026Grant
Filed
Aug 26, 2026, 4:10 PM ET26-day reporting delay
Accession
0001493152-26-040238Code A · Transaction 102740
How reported position traded is calculated

Calculated only for code-P purchases and code-S sales.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Jul 31, 2026Grant150,000$0.41$61,500Trade 102741
2 transaction rows in this filing. Joint filers share the same rows.

Filing warnings

Notes recorded with this filing
1 warning
delayed filingThe filing was reported 26 calendar days after the transaction date.

VVOS price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
VVOS · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago1w ago1d ago
Returns since7d −32%30d −44%90d180d1y

Footnotes in full

F1: On July 31, 2026 (the "Grant Date"), the Reporting Person received a grant of 150,000 stock options, which grant was made under the Issuer's 2024 Omnibus Equity Incentive Plan. Stock options shall vest and become exercisable at the rate of 25,000 shares per month from November 1, 2026 through April 1, 2026.